CB2 has previously been suggested to play a key role in suppressing immune activity in cancer, a concept supported by Zhu et al., who showed that CB2 controls tumor immunity of lung cancer by increasing the levels of Th2 cytokines like IL-10 and TGF, and by downregulating the Th1 cytokine IFN-γ (10). The gene discussed is IFNG; the disease is neoplasm.